Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Pfister

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Regulatory Toxicology and Pharmacology : RTP|January 8, 2013
Guidance on the establishment of acceptable daily exposure limits (ADE) to support Risk-Based Manufacture of Pharmaceutical ProductsEdward V Sargent, Ellen Faria, Thomas Pfister, et al.
Digital Biomarkers|January 15, 2024
Why Language Matters in Digital Endpoint Development: Harmonized Terminology as a Key Prerequisite for Evidence GenerationLada Leyens, Carrie A Northcott, Lesley Maloney, et al.
Regulatory Toxicology and Pharmacology : RTP|October 28, 2018
Use of the permitted daily exposure (PDE) concept for contaminants of intravitreal (IVT) drugs in multipurpose manufacturing facilitiesEster Lovsin Barle, Thomas Pfister, Cornelia Fux, et al.
The Journal of Experimental Medicine|March 16, 2005
Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1Dominique Gatto, Thomas Pfister, Andrea Jegerlehner, et al.
Regulatory Toxicology and Pharmacology : RTP|May 26, 2016
A harmonization effort for acceptable daily exposure derivation - Considerations for application of adjustment factorsRobert G Sussman, Bruce D Naumann, Thomas Pfister, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|March 8, 2008
Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safetyAnke Lühe, Klaus-Peter Künkele, Monika Haiker, et al.
Critical Reviews in Toxicology|January 24, 2015
Contribution of new technologies to characterization and prediction of adverse effectsDavid Rouquié, Marjoke Heneweer, Jane Botham, et al.
The Annals of Occupational Hygiene|June 25, 2014
Bioavailability of therapeutic proteins by inhalation--worker safety aspectsThomas Pfister, David Dolan, Joel Bercu, et al.
Journal of Molecular Endocrinology|March 7, 2013
Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and manFranziska Boess, Cristina Bertinetti-Lapatki, Sannah Zoffmann, et al.
Chest|September 11, 2022
Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE)Luke S Howard, Stephan Rosenkranz, Robert P Frantz, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Regulatory Toxicology and Pharmacology : RTP|January 8, 2013
Guidance on the establishment of acceptable daily exposure limits (ADE) to support Risk-Based Manufacture of Pharmaceutical ProductsEdward V Sargent, Ellen Faria, Thomas Pfister, et al.
Digital Biomarkers|January 15, 2024
Why Language Matters in Digital Endpoint Development: Harmonized Terminology as a Key Prerequisite for Evidence GenerationLada Leyens, Carrie A Northcott, Lesley Maloney, et al.
Regulatory Toxicology and Pharmacology : RTP|October 28, 2018
Use of the permitted daily exposure (PDE) concept for contaminants of intravitreal (IVT) drugs in multipurpose manufacturing facilitiesEster Lovsin Barle, Thomas Pfister, Cornelia Fux, et al.
The Journal of Experimental Medicine|March 16, 2005
Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1Dominique Gatto, Thomas Pfister, Andrea Jegerlehner, et al.
Regulatory Toxicology and Pharmacology : RTP|May 26, 2016
A harmonization effort for acceptable daily exposure derivation - Considerations for application of adjustment factorsRobert G Sussman, Bruce D Naumann, Thomas Pfister, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|March 8, 2008
Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safetyAnke Lühe, Klaus-Peter Künkele, Monika Haiker, et al.
Critical Reviews in Toxicology|January 24, 2015
Contribution of new technologies to characterization and prediction of adverse effectsDavid Rouquié, Marjoke Heneweer, Jane Botham, et al.
The Annals of Occupational Hygiene|June 25, 2014
Bioavailability of therapeutic proteins by inhalation--worker safety aspectsThomas Pfister, David Dolan, Joel Bercu, et al.
Journal of Molecular Endocrinology|March 7, 2013
Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and manFranziska Boess, Cristina Bertinetti-Lapatki, Sannah Zoffmann, et al.
Chest|September 11, 2022
Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE)Luke S Howard, Stephan Rosenkranz, Robert P Frantz, et al.
Pageof 4